Medical Research Commercialisation Fund (MRCF)
VC Fund
Melbourne, Australia
Medical Research Commercialisation Fund (MRCF) is a VC fund in Melbourne focused on Biotechnology and Health Care. Medical Research Commercialisation Fund (MRCF) provides dedicated, investment funding to support the commercialisation of early-stage medical research discoveries that originate from its member institutes. The collaborative nature of the MRCF seeks to foster best practice in the commercialisation of medical innovations.
- Total investments:
- 29
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Medical Research Commercialisation Fund (MRCF) invests in
Stages Medical Research Commercialisation Fund (MRCF) invests in
Countries Medical Research Commercialisation Fund (MRCF) invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Series A
- $1.3M–$13M
Investment Focus
Industry
- Biotechnology 17 (59%)
- Health Care 16 (55%)
- Medical 14 (48%)
- Therapeutics 7 (24%)
- Medical Device 7 (24%)
Stage
- Series A 10 (34%)
- Seed 9 (31%)
- Funding Round 3 (10%)
- Series B 2 (7%)
- Venture - Series Unknown 2 (7%)
Country
- Australia 19 (66%)
- United Kingdom 3 (10%)
- United States 2 (7%)
- India 1 (3%)
- Israel 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Chris Nave
Principal Executive
|
Principal Executive | Total investments: 18 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
MycRx
|
MecRx is a drug development company that works on new treatments for cancer and novel mechanism of action antibiotics. Using proprietary “hit identification” technology, MecRx is developing inhibitors of cMyc, a protein that is deregulated in over 50% of all human cancers. MecRx draws on the expertise of the Peter MacCallum Cancer Centre and CSIROand is headquartered in Melbourne, Australia.MecRx was founded in 2013 by an ex-pharma/biotech team. MecRx is run as a virtual company based in Melbourne, Australia and its shareholders and service providers include the Peter MacCallum Cancer Institute and CSIRO. The company secured $5m Series A investment from the MRCF (www.mrcf.com.au) and CSIRO in 2015. | Venture - Series Unknown / Feb 10, 2023 | |
Currus Biologics
|
Currus Biologics is a biotechnology company that develop CAR-T cell therapies for the treatment of solid tumour cancers. | $7.5M / Series A / Jun 29, 2021 | |
Azura Ophthalmics
|
Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatmentoptions are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S. | $20M / Series C / Oct 22, 2020 | |
Cincera Therapeutics
|
Cincera Therapeutics is a privately held biotechnology company. | $725.3K / Grant / Sep 03, 2020 | |
Glyscend Therapeutics
|
Glyscend develops a revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway. Thecompany's technology is an orally ingestible intestinal coating that prevents the stimulation of duodenal mucosa and inhibits key neurohormonal pathways in the proximal gut. Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. Meanwhile, the company aims to provide endocrinologists and primary care physicians with the innovative tools they need to treat the disease instead of merely managing it. It was founded in 2014 by co-founders Ashish Nimgaonkar, Michael Parlato, and Pratik Patel. | $19.8M / Series A / Jun 11, 2020 | |
George Medicines
|
George Medicines is a drug manufacturing company that improves the management of non-communicable diseases. | $35.3M / Venture - Series Unknown / Mar 09, 2020 | |
Pathios Therapeutics
|
Pathios Therapeutics is a biotech company focused on the development of therapies for autoimmune diseases and cancer. | $13.2M / Series A / Dec 18, 2019 | |
Denteric
|
Denteric is developing a vaccine based on research conducted at the University of Melbourne, with collaborative support from CSL Limited, to fight the disease and will receive the money in three parts each year from 2019 to 2021. | $9.4M / Series A / Sep 25, 2019 | |
Paragen Bio
|
Paragen Bio is a provider of a technology intended to treat autoimmune diseases. The company's technology helps in treating diseases which causes the immune system to attack healthy tissues and organs, enabling doctors to stop the deterioration and complete destruction of tissue. | $4M / Aug 14, 2018 | |
Certa
|
Certa is an operational management platform that provides a fully integrated suite of products for third-party lifecycle management. The company's automated SaaS platform is used for business-to-business interactions, including on-boarding, due diligence, risk mitigation, and monitoring of third-party relationships. | Seed / Jun 05, 2018 | |
| See all 29 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Medical Research Commercialisation Fund (MRCF) invest in?
Medical Research Commercialisation Fund (MRCF) invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Seed stage. Most of the 29 investments tracked by Shizune back companies in Australia. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Medical Research Commercialisation Fund (MRCF)'s check size?
Medical Research Commercialisation Fund (MRCF) typically joins rounds of $1.3M–$13M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Medical Research Commercialisation Fund (MRCF) participates in.
How do I contact Medical Research Commercialisation Fund (MRCF)?
Public channels for Medical Research Commercialisation Fund (MRCF) include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Medical Research Commercialisation Fund (MRCF)?
The team at Medical Research Commercialisation Fund (MRCF) includes Chris Nave (Principal Executive). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
